Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.

In the cytoplasm of virtually all clear-cell renal cell carcinoma (ccRCC), speckle-type POZ protein (SPOP) is overexpressed and misallocated, which may induce proliferation and promote kidney tumorigenesis. In normal cells, however, SPOP is located in the nucleus and induces apoptosis. Here we show that a structure-based design and subsequent hit optimization yield small molecules that can inhibit the SPOP-substrate protein interaction and can suppress oncogenic SPOP-signaling pathways. These inhibitors kill human ccRCC cells that are dependent on oncogenic cytoplasmic SPOP. Notably, these inhibitors minimally affect the viability of other cells in which SPOP is not accumulated in the cytoplasm. Our findings validate the SPOP-substrate protein interaction as an attractive target specific to ccRCC that may yield novel drug discovery efforts.

[1]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[2]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[3]  M. Tyers,et al.  The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase , 2003, Nature.

[4]  Long Yu,et al.  Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants , 2014, Cell reports.

[5]  M. Pagano,et al.  Specific small molecule inhibitors of Skp2-mediated p27 degradation. , 2012, Chemistry & biology.

[6]  C. Joe,et al.  BTB/POZ domain of speckle‐type POZ protein (SPOP) confers proapoptotic function in HeLa cells , 2007, Biofactors.

[7]  Christopher D. Brown,et al.  Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer , 2009, Science.

[8]  Yi Sun,et al.  Targeting E3 Ubiquitin Ligases for Cancer Therapy , 2003, Cancer biology & therapy.

[9]  S. Dalton,et al.  MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. , 2013, Genes & development.

[10]  Yi Sun,et al.  SCF E3 ubiquitin ligases as anticancer targets. , 2011, Current cancer drug targets.

[11]  J. Manola,et al.  Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. , 2012, The Journal of urology.

[12]  Aaron Ciechanover,et al.  The ubiquitin–proteasome pathway: on protein death and cell life , 1998, The EMBO journal.

[13]  B. O’Malley,et al.  Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1 , 2011, Oncogene.

[14]  A. Ciulli,et al.  Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation , 2015, The Biochemical journal.

[15]  Y. Muro,et al.  Identification of a novel nuclear speckle‐type protein, SPOP , 1997, FEBS letters.

[16]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[17]  K. Nakayama,et al.  Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.

[18]  James Brugarolas,et al.  Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.

[19]  E. Gelmann,et al.  The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Dong Yang,et al.  Acetylation-Mediated Proteasomal Degradation of Core Histones during DNA Repair and Spermatogenesis , 2013, Cell.

[21]  Kevin P. White,et al.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. , 2014, Cancer cell.

[22]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Hung,et al.  Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression , 2013, Cell.

[24]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[25]  J. Pedraza-Chaverri,et al.  Cullin 3 as a novel target in diverse pathologies☆ , 2013, Redox biology.

[26]  Dmitri A. Nusinow,et al.  Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Chène,et al.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.

[28]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[29]  Jong-Bok Yoon,et al.  Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex. , 2011, Biochemical and biophysical research communications.

[30]  Tilman Grune,et al.  The proteasomal system. , 2009, Molecular aspects of medicine.

[31]  J Wade Harper,et al.  Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. , 2009, Molecular cell.

[32]  C. Chien,et al.  A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. , 2006, Developmental cell.

[33]  Yi Sun.  E3 ubiquitin ligases as cancer targets and biomarkers. , 2006, Neoplasia.

[34]  D. Bernard,et al.  Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment , 2014, Journal of medicinal chemistry.